Recent 8-K filings for GOSS

• July 14, 2026, 8:39 PM ET other material materiality 0.65 neutral item 5.02item 5.03item 5.07item 9.01

  Gossamer Bio stockholders approve 4B authorized shares, new incentive plan, and note/warrant issuance

  Stockholders approved charter amendment increasing authorized common shares from 700M to 4B.

• June 17, 2026, 8:01 AM ET debt materiality 0.70 positive item 7.01item 9.01

  Gossamer Bio completes exchange of 94.5% of 2027 notes; $18.9M remain outstanding

  $181.1M principal (94.5%) of 5% 2027 notes tendered; exchanged for new 7.5% 2030 notes and equity.

• June 4, 2026, 7:28 PM ET debt materiality 0.85 neutral item 1.01item 1.02item 2.03item 3.02item 7.01item 9.01 ◈ Equity Issuances ×4◈ Material Agreements ×2◈ Debt Financings

  Gossamer Bio exchanges 90.5% of 5% notes for new 7.5% notes, stock, and warrants

  $181M of 5% Convertible Senior Notes due 2027 tendered and cancelled (90.5% of outstanding).

• June 2, 2026, 8:00 AM ET debt materiality 0.65 neutral item 8.01item 9.01

  Gossamer Bio extends early tender deadline for exchange offer; $181M of notes tendered

  Early tender deadline extended to 5:00 p.m. ET on June 2, 2026; early settlement expected June 4, 2026.

• May 18, 2026, 7:06 AM ET debt materiality 0.85 neutral item 1.01item 2.02item 5.02item 7.01item 8.01item 9.01 ◈ Earnings Releases◈ Material Agreements

  Gossamer Bio launches exchange offer for 5.00% notes; holders of 75.2% support

  Exchange Offer: up to $72M new 7.50% Convertible Secured Notes due 2030, plus up to 317.6M common shares and 150M Purchase Warrants.

• April 9, 2026, 7:59 PM ET other material materiality 0.75 negative item 3.01 ◈ Listing & Compliance Notices

  Gossamer Bio receives Nasdaq bid price deficiency notice; 180 days to cure

  Nasdaq notified Gossamer on April 8, 2026 that stock bid price <$1.00 for 30 consecutive business days (Feb 24 – Apr 7, 2026).

• March 17, 2026, 7:59 PM ET other material materiality 0.90 negative item 2.02item 9.01 ◈ Earnings Releases

  Gossamer Bio reports 2025 net loss $170.4M; seralutinib Phase 3 narrowly missed primary endpoint

  PROSERA Phase 3 in PAH showed placebo-adjusted 6MWD +13.3 meters but missed prespecified statistical alpha of 0.025 (p=0.0320).

• February 23, 2026, 6:59 PM ET other material materiality 0.85 neutral item 8.01item 9.01

  Gossamer Bio Phase 3 PROSERA trial misses primary endpoint, seralutinib shows signals in high-risk PAH

  Primary 6MWD endpoint missed: +13.3m placebo-adjusted (p=0.0320 vs prespecified α=0.025).

• November 5, 2025, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Gossamer Bio Q3 net loss $48.2M; PROSERA topline due Feb 2026

  Net loss of $48.2M ($0.21 per share) vs $30.8M loss a year ago; revenue from Chiesi collab $13.3M.

• September 25, 2025, 7:59 PM ET other material materiality 0.60 neutral item 3.02 ◈ Equity Issuances ×3

  Gossamer Bio issues 2.5M shares for option to acquire Respira Therapeutics

  Issued 2,500,000 shares to Prana Bio on Sept 24, 2025 as consideration for option to acquire Respira via merger.

• August 5, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Gossamer Bio Q2 net loss $38.3M; PROSERA Phase 3 topline due Feb 2026

  Net loss $38.3M ($0.17 per share) vs net income $49.2M in Q2 2024, driven by $88.8M one-time license revenue in prior year.

• June 16, 2025, 7:59 PM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

  Gossamer Bio completes enrollment in Phase 3 PROSERA study for seralutinib in PAH (n=390)

  Global registrational Phase 3 PROSERA study fully enrolled; topline results expected February 2026.

• May 15, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Gossamer Bio closes new patient screening in PAH Phase 3 PROSERA study; Q1 net loss $36.6M

  Enrollment of 343 patients completed; to exceed 350 by early June; topline results expected Feb 2026.

• March 13, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Gossamer Bio Q4 2024 net loss $33M; PROSERA Phase 3 topline due Q4 2025

  Cash, equivalents and marketable securities $294.5M at year-end; runway into H1 2027.

• November 7, 2024, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Gossamer Bio Q3 net loss $30.8M; cash $327M, runway into H1 2027

  Net loss of $30.8M ($0.14/share) vs $40.0M ($0.21/share) in Q3 2023; revenue from Chiesi collaboration was $9.5M.

• September 13, 2024, 7:59 PM ET other material materiality 0.70 negative item 3.01

  Gossamer Bio receives Nasdaq bid-price deficiency notice; deadline March 2025

  Nasdaq notified Gossamer Bio that its stock failed to maintain $1.00 minimum bid for 30 consecutive business days through Sept 10, 2024.

• August 12, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Gossamer Bio Q2 2024 net income $49.2M; cash $354.5M; Chiesi collaboration on track

  Net income $49.2M ($0.22 basic EPS) vs net loss $42.5M in Q2 2023.

• May 24, 2024, 7:59 PM ET other material materiality 0.60 negative item 3.01

  Gossamer Bio receives Nasdaq minimum bid deficiency; cure period to Nov 18, 2024

  Nasdaq notice on May 22, 2024; stock below $1.00 for 30 consecutive business days through May 21.

• May 7, 2024, 7:59 PM ET other material materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Gossamer Bio reports Q1 net loss $41.9M; announces Chiesi collaboration for seralutinib

  Chiesi collaboration provides $160M upfront; Gossamer and Chiesi split global development costs, profits in US.

• May 6, 2024, 7:59 PM ET M&A materiality 0.90 positive item 1.01item 1.02item 3.02item 8.01item 9.01 ◈ Material Agreements

  Gossamer Bio enters global collaboration with Chiesi for seralutinib; receives $160M upfront

  Receives $160M development reimbursement; eligible for up to $146M regulatory and $180M sales milestones.

• March 12, 2024, 7:59 PM ET leadership materiality 0.60 positive item 5.02item 9.01 ◈ executive_change ×2

  Gossamer Bio appoints Dr. Nathan (PH-ILD expert) and biotech analyst Drynan to board

  Dr. Steven Nathan appointed as Class I director, effective March 11, 2024; brings pulmonary and PH-ILD expertise.

• March 5, 2024, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01 ◈ Earnings Releases

  Gossamer Bio Q4/FY23 results: first PAH patient dosed in Phase 3 PROSERA, cash $296M into H1 2026

  First PAH patient dosed in registrational Phase 3 PROSERA study; topline results expected Q4 2025.

• March 4, 2024, 6:59 PM ET regulatory materiality 0.60 positive item 8.01

  Gossamer Bio regains Nasdaq minimum bid price compliance; deficiency closed

  Received Nasdaq letter on March 4, 2024 confirming compliance with minimum bid price rule.

• November 9, 2023, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01 ◈ Earnings Releases

  Gossamer Bio Q3 net loss $40M, cash sufficient into H1 2026; PROSERA study ahead

  Net loss $40.0M ($0.21/share) vs $59.4M loss in Q3 2022; R&D expenses $31.2M (down from $44.5M).

• October 20, 2023, 7:59 PM ET regulatory materiality 0.70 negative item 3.01 ◈ Listing & Compliance Notices

  Gossamer Bio receives Nasdaq notice for non-compliance with $1.00 minimum bid price; 180-day cure period.

  Nasdaq notified Gossamer Bio on Oct 19, 2023 that its common stock had a closing bid price below $1.00 for 30 consecutive business days.

• August 8, 2023, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases

  Gossamer Bio Q2 net loss $42.5M; raises $212M in July private placement

  Net loss $42.5M ($0.45/share) vs $56.5M ($0.74) in Q2 2022; R&D expenses decreased to $36.3M.

• July 20, 2023, 7:59 PM ET other material materiality 0.85 neutral item 1.01item 3.02item 7.01item 9.01 ◈ Material Agreements

  Gossamer Bio raises $212M in private placement; discloses interim TORREY OLE data and PROSERA Phase 3 design

  Sold 129.9M shares + warrants to purchase 32.5M shares at combined price $1.63125 per unit for gross proceeds ~$212M.

• May 9, 2023, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases

  Gossamer Bio Q1 net loss $49.2M; advancing seralutinib to Phase 3 in PAH

  Net loss of $49.2M ($0.52 per share) for Q1 2023 vs. $57.8M ($0.76) in Q1 2022.

• April 3, 2023, 7:59 PM ET regulatory materiality 0.90 negative item 8.01

  Gossamer Bio discontinues GB5121 after FDA partial clinical hold; SAEs included fatal hemorrhage

  FDA placed partial clinical hold on all GB5121 trials after atrial fibrillation, sudden death, and fatal intracranial hemorrhage in STAR-CNS study.

• March 17, 2023, 7:59 PM ET other material materiality 0.60 neutral item 2.02item 9.01 ◈ Earnings Releases ×2

  Gossamer Bio pauses GB5121 enrollment, advances seralutinib Phase 3

  Seralutinib Phase 3 in PAH to start H2 2023; dose 90 mg BID, primary endpoint 6-minute walk distance.

• December 6, 2022, 6:59 PM ET other material materiality 0.80 positive item 8.01item 9.01

  Gossamer Bio's Phase 2 TORREY study meets primary endpoint; seralutinib reduces PVR in PAH

  Phase 2 TORREY met primary endpoint: placebo-corrected PVR reduction of 96.1 dynes (14.3%, p=0.031).

• August 9, 2022, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01

  Gossamer Bio Q2 net loss $56.5M; seralutinib Phase 2 readout on track for Nov/Dec 2022

  Net loss of $56.5M ($0.74/share) vs $59.8M ($0.80/share) in Q2 2021.

• July 13, 2022, 7:59 PM ET other material materiality 0.70 positive item 1.01item 3.02item 7.01item 9.01

  Gossamer Bio raises $120M via private placement of 16.6M shares at $7.21/share

  Private placement of 16.6M shares at $7.21; gross proceeds ~$120M before expenses.

• May 10, 2022, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Gossamer Bio Q1 net loss $57.8M ($0.76/diluted); TORREY enrollment complete; cash $271.6M

  Phase 2 TORREY study (seralutinib in PAH) completed enrollment; topline data expected Q4 2022.

• April 25, 2022, 7:59 PM ET other material materiality 0.85 negative item 2.02item 8.01

  Gossamer Bio Phase 2 SHIFT-UC trial of GB004 misses primary endpoint; study terminated

  Phase 2 trial of GB004 in mild-to-moderate active UC failed primary endpoint at week 12 (15.4% QD, 22.5% BID vs. placebo 17.9%).

• March 3, 2022, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Gossamer Bio reports FY2021 net loss of $234M; cash $325M; pipeline milestones set for 2022

  Net loss for Q4 2021 was $56.3M ($0.74/share); FY2021 net loss $234M ($3.13/share).

• November 8, 2021, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Gossamer Q3 net loss $60.2M ($0.80/shr); PAH study topline delayed to H2 2022

  Net loss $60.2M for Q3 2021 vs $57.8M prior year, R&D $43.2M, G&A $12.5M.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.65 · Most common event other_material

13 positive 8 negative 29 neutral

source · GOSS on sec.gov